<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6961902/results/search/test_trace/results.xml">
  <result pre="are credited.pone.0227532.pdf Abstract Objectives To assess the potency of anti-viral" exact="treatment" post="for hepatitis B virus-associated glomerulonephritis (HBV-GN). Method: We searched"/>
  <result pre="Hepatitis Be Antigen (HBeAg) were significantly higher in the anti-viral" exact="treatment" post="group than in the control group (OR = 27.08,"/>
  <result pre="and vaccination against the hepatitis B virus (HBV), chronic HBV" exact="infection" post="remains a significant socioeconomic burden. The global prevalence of"/>
  <result pre="chronic HBV infection remains a significant socioeconomic burden. The global" exact="prevalence" post="of chronic HBV in 2016 was close to 3.9%,"/>
  <result pre="the risk of activating viral infections, so the mainstay of" exact="treatment" post="continues to be antiviral therapy. Several drugs are now"/>
  <result pre="be antiviral therapy. Several drugs are now available for the" exact="treatment" post="of chronic HBV infection and are mainly one of"/>
  <result pre="drugs are now available for the treatment of chronic HBV" exact="infection" post="and are mainly one of two types: nucleos (t)"/>
  <result pre="HBV-GN patients; three studies[4,6,7] focused on the effects of antiviral" exact="treatment" post="on HBV-GN but were completed before 2011. However, previous"/>
  <result pre="investigators did not provide details regarding to therapies, such as" exact="treatment" post="for patients of different ages, antiviral drug selection or"/>
  <result pre="treatment for patients of different ages, antiviral drug selection or" exact="treatment" post="duration. Standardized treatment guidelines that are personalized and appropriate"/>
  <result pre="of different ages, antiviral drug selection or treatment duration. Standardized" exact="treatment" post="guidelines that are personalized and appropriate for the current"/>
  <result pre="planned to explore potential sources of variability in the observed" exact="treatment" post="effects. When possible, subgroup analyses were performed for clinical"/>
  <result pre="criteria, 56 of these studies were excluded after the full-text" exact="screening" post="(Fig 1). Fig 1 Flow chart of study selection."/>
  <result pre="units, 3 times/week, subcutaneous injection)(n = 5) diuretic agents/dipyridamole /no" exact="treatment" post="(n = 11) 12 weeks 55.1 mo 0 ①②③"/>
  <result pre="We evaluated the CR and total remission (CR+PR) rates after" exact="treatment" post="with a fixed-effect model (Fig 2). There was no"/>
  <result pre="remission rate of proteinuria was obviously higher in the antiviral" exact="treatment" post="group than in the control group in all studies"/>
  <result pre="all studies (OR = 10.48, 95% CI: 4.60−23.89). The antiviral" exact="treatment" post="significantly affected CR in all trials (OR = 11.64,"/>
  <result pre="effects of IFNs and NAs, we analyzed two subgroups. NA" exact="treatment" post="for HBV-GN was assessed in 4 studies, and IFN"/>
  <result pre="treatment for HBV-GN was assessed in 4 studies, and IFN" exact="treatment" post="was assessed in 3 studies. Panomsak’s[20] study included only"/>
  <result pre="CI: 1.56−106.41) of proteinuria was obviously higher in the antiviral" exact="treatment" post="group than in the control group. Heterogeneity using the"/>
  <result pre="with CR, the quantity of PR could not reflect the" exact="treatment" post="effects, so our study focused on total remission (CR+PR)"/>
  <result pre="efficacy of these trials differed. To make accurate decisions regarding" exact="treatment" post="for different groups of patients and explore the sources"/>
  <result pre="results didn’t show significant improvement in renal function, especially under" exact="treatment" post="of NAs. Our results showed that antiviral therapy could"/>
  <result pre="HBeAg, were essential in the pathogenesis of HBV-GN. (2) HBV" exact="infection" post="of nephrocytes induces a cytopathic effect[33]. Thus, the hypothesis"/>
  <result pre="to mitigate proteinuria, and they required a shorter duration of" exact="treatment" post="than did adults. Therefore, we think that further implementation"/>
  <result pre="for NAs. We conclude that an individualized therapy program considering" exact="treatment" post="efficacy and side effects is the best option for"/>
  <result pre="reduced the strength of our final conclusions. Second, dosage and" exact="treatment" post="duration for drug administration and the follow-up duration might"/>
  <result pre="This geographic concentration is probably the reason for the high" exact="prevalence" post="of HBV infection in these countries. As a result,"/>
  <result pre="is probably the reason for the high prevalence of HBV" exact="infection" post="in these countries. As a result, our conclusions concerning"/>
  <result pre="strengthen the evidence that antiviral therapy is effective in antiviral" exact="treatment" post="groups compared to control groups. It was particularly effective"/>
  <result pre="improving HBeAg clearance but failed to improve the eGFR. Antiviral" exact="treatment" post="has a definite therapeutic effect on children, and IFNs"/>
  <result pre="TPO. Global prevalence, treatment, and prevention of hepatitis B virus" exact="infection" post="in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403."/>
  <result pre="AldemirMN, ArslanY, BayanK, et al.Effects of entecavir, tenofovir and telbivudine" exact="treatment" post="on renal functions in chronic hepatitis B patients. Acta"/>
  <result pre="26LiawYF. HBeAg seroconversion as an important end point in the" exact="treatment" post="of chronic hepatitis B. Hepatol Int. 2009; 3(3):425–33. 10.1007/s12072-009-9140-319669245"/>
 </snippets>
</snippetsTree>
